Table 2. Uni- and multivariate analysis of baseline predictors of SVR to HCV triple therapy.
| Patient characteristics | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| continuous variables in [median (range)] | |||||
| Virologic Failure | SVR | P-value | OR (95% CI) | P-value | |
| n = 44 | n = 121 | ||||
| Age (years) | 50 (33–66) | 50 (29–74) | 0.8* | ||
| BMI (kg/m2) | 26.6 (21.1–28.4) | 25.1 (18.4–36.3) | 0.6* | ||
| Female sex [n (%)] | 9 (20.5%) | 51 (42.2%) | 0.02*** | 3.7994 (1.3474–10.7181) | 0.01 |
| ALT [times upper limit of normal] | 2.9 (0.7–11.0) | 1.7 (0–12.8) | 0.0007* | ||
| AST [times upper limit of normal] | 2.7 (0.6–7.5) | 1.4 (0.1–6.7) | <0.0001* | 53.4759 (7.8616–357.1429-) | <0.0001 |
| GGT [times upper limit of normal] | 2.8 (0.3–10.3) | 1.2 (0.2–8.8) | <0.0001* | ||
| Bilirubin [mg dL-1] | 0.6 (0.1–3.5) | 0.5 (0.2–2.1) | 0.09* | ||
| HCV viral load [IU/mL] | 2.6x106 | 1.4x106 | 0.1* | ||
| IP10 [pg/mL] | 457 (122–2941) | 398 (94–2001) | 0.02* | ||
| IFNL4 rs12979860 CC/non-CC [n (%)] | 6/44 (13.6%) | 40/114 (35.1%) | 0.01*** | 4.7483 (1.4824–15.1976-) | 0.009 |
| HCV subtype 1b [n (%)] | 20 (45.5%) | 71 (58.7%) | 0.2*** | ||
| Prior Null Response [n (% pretreated patients)] | 9/28 (32.1%) | 11/67 (16.4%) | 0.2*** | ||
| Liver cirrhosis [n (%)] | 50% | 20.7% | 0.0005*** | ||
| NS3 RAVs [n (%)] | 3 (6.8%) | 1 (0.8%) | 0.06** | ||
| NS3 phenotypes [IC50 fold change] | 0.8501 (0.3279–3.9233)# | 1.0200 (0.2927–5.0340)# | 0.2* | ||
| NS3 phenotypes >2-fold change | 4/33 (12.2%) | 4/51 (7.8%) | 0.7** | ||
P values of univariate analyses are uncorrected for multiple testing
*Wilcoxon Mann Whitney U Test
**Fisher exact test for n<20
***Chi-square test
# NS3 phenotyping was performed in a subgroup of patients (n = 33, virologic failure; n = 55, SVR)
OR: Odds ratio, 95% CI, 95% confidence interval